Mabano, Concepcion P.

HRN: 20-30-99  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/21/2022
LEVOFLOXACIN 500MG (TAB)
04/21/2022
04/28/2022
PO
750mg
OD
Empirical Escalation
Waiting Final Action 
04/24/2022
CEFTAZIDIME 1GM (VIAL)
04/24/2022
05/01/2022
IVT
1g
Q8
SEPSIS WBC 30.4
Waiting Final Action 
04/24/2022
LEVOFLOXACIN 500MG (TAB)
04/24/2022
05/01/2022
ORAL
750mg
OD
Sepsis
Waiting Final Action 
04/27/2022
MUPIROCIN 2%, 15G (TUBE)
04/27/2022
05/04/2022
TOPICAL
BID
BID
Bed Sores
Waiting Final Action 
05/02/2022
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
05/02/2022
05/08/2022
IVTT
4.5
Q6
SEPSIS
Waiting Final Action 
05/02/2022
MUPIROCIN 2%, 15G (TUBE)
05/02/2022
05/08/2022
TOPICAL
TID
TID
Decubitus Ulcer
Waiting Final Action 
05/13/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
05/13/2022
05/20/2022
IV
4.5g
Q8
Pleural Effusion Right, Prob Sec To HAP
Waiting Final Action 
05/13/2022
MUPIROCIN 2%, 15G (TUBE)
05/13/2022
05/20/2022
LOCAL
2%
BID
Decubitus Ulcer
Waiting Final Action 
05/13/2022
CEFTAZIDIME 1GM (VIAL)
05/13/2022
05/21/2022
IV
1gm
Q8
Pleural Effusion Right; Allergic Reaction To Pip-Taz
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: